AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03244306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
Description: Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
Study NCT04479787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Utilization of BURSTDR stimulation
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: IV or CIVI
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: IV or CIVI
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: IV or CIVI
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: oral
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: CIVI
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: IV
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: IV
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: IV
Study NCT02672748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden
Description: Two years of financial and technical home gardening support for new gardeners
Study NCT03564977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
Study NCT02196025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
Study NCT00200720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Atkins diet (low carbohydrate diet)
Study NCT00200720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet (high carbohydrate diet)
Study NCT02045095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).
Study NCT03516422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULTRASOUND DEBRIDEMENT
Description: Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
Study NCT03516422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: STANDARD CARE GROUP
Description: The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
Study NCT02255227 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: one dose for arm 1 and 2 doses for arm 2
Study NCT02255227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: one dose for arm 1 and 2 doses for arm 2
Study NCT02255227 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23
Description: one dose
Study NCT02255227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumo 23
Description: one dose
Study NCT02134717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
Study NCT02134717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with bronchoalveolar lavage
Description: Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
Study NCT02134717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venipunctures
Description: Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
Study NCT02134717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
Study NCT03930602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Participants will receive BMS-986165.
Study NCT03930602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Participants will receive fluvoxamine.
Study NCT01632891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants received one 600 mg tablet of efavirenz orally once daily.
Study NCT01632891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
Study NCT01632891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Description: Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
Study NCT02129075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given SC or ID
Study NCT02129075 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given SC or ID
Study NCT02129075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study NCT02129075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly ICLC
Description: Given SC
Study NCT02129075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Flt3 Ligand
Description: Given SC
Study NCT02555995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT scan (as yet unnamed)
Description: OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
Study NCT04033003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group ANC
Description: Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
Study NCT04479787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Assessing type of CMM, location and frequency.
Study NCT02398266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)
Description: Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
Study NCT03294603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: 1mg \[14C\]-CC-220 will be administered as a single dose
Study NCT03294603 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]
Description: Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
Study NCT01457495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib (Infanrix-hexa™)
Description: 3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
Study NCT01457495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-IPV/Hib (Infanrix-IPV/Hib™)
Description: 3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
Study NCT04243811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: LLLT with dental needle for local anesthesia during dental treatment
Study NCT04243811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical anesthesia
Description: topical anesthesia with dental needle for local anesthesia during dental treatment
Study NCT02223520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin and Chlorhexidine
Study NCT02223520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment and placebo cloths
Study NCT03194594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride, dexamethasone, and combination of two drugs
Description: After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
Study NCT01457495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV (Engerix™-B)
Description: 3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
Study NCT01959646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract Supplementation Group
Description: Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
Study NCT01959646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard for Groups
Description: To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
Study NCT01959646 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard for Groups
Description: To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
Study NCT01959646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to consume three (3) placebo capsules with food twice a day.
Study NCT03693768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Health coaching
Study NCT03377946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotics
Description: the probiotics group was taking probiotics 4 packets a day
Study NCT03377946 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo group was taking placebo 4 packets a day
Study NCT02825069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early introduction of solid foods
Description: Early introduction of solid foods
Study NCT06034054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing counceling
Description: * Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive.
Study NCT04400721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block with ropivacaine 3.75mg/ml
Description: Single shot erector spinae block
Study NCT01405638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: One-on-one client-centered counseling for lifestyle changes related to blood pressure control
Study NCT04671251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEVI-007
Description: 50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
Study NCT03638700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide™ angled tip
Description: Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
Study NCT03638700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide2™ angled tip
Description: Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
Study NCT03638700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide™ straight tip
Description: Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
Study NCT03638700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide2™ straight tip
Description: Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
Study NCT03807947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial TAE - Bland embolization with 40-100 Microparticles
Description: TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
Study NCT03807947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral TAE - Bland embolization with 40-100 Microparticles
Description: TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
Study NCT00992693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (Virazole) Injection
Description: The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60.
Study NCT05025553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gut mobilization
Description: Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
Study NCT02774876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient's insulin pump
Description: The patient's insulin pump will be used to regulate glucose levels.
Study NCT02774876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Patient's usual fast-acting insulin analog will be used.
Study NCT02774876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Description: The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
Study NCT02774876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop
Description: Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
Study NCT04119778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise, Tai chi
Description: They are aerobic and mind-body exercise respectively.
Study NCT03194594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride, dexamethasone, and combination of two drugs
Description: After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
Study NCT04472273 — intervention group
Intervention type: PROCEDURE
Intervention: high-flow nasal cannula / classic nasal cannula
Description: The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
Study NCT03830073 — intervention group
Intervention type: GENETIC
Intervention: Measurement of VDR genetic polymorphism
Description: VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
Study NCT03611452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Episiotomy
Description: repair of perineal muscles and skin
Study NCT03611452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Episiotomy
Description: repair of perineal muscles and skin
Study NCT03652129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disinfection
Description: Disinfection maneuver using LASER and nano irrigant